In addition, recent ADAGIO phase 2 trial results of the Wee1 inhibitor adavosertib (AZD1775) demonstrating response rates of 30% in uterine serous carcinoma are promising and warrant further investigation [17]. The gene discussed is WEE1; the disease is endometrial serous adenocarcinoma.